Imprimer

Articles médicaux concernant les MAT

Écrit par Paul Coppo
RECOMMANDATIONS
Recommandations du cnr-mat publiées sous l'égide de la Société de Réanimation de Langue Française et de la Société Française d'Hématologie.
ARTICLES EN FRANÇAIS
L’activité de télémédecine dans les microangiopathies thrombotiques : un progrès dans les maladies rares nécessitant une prise en charge en urgence [Telemedicine in thrombotic microangiopathies: A way forward in rare diseases requiring emergency care]. Coppo P, Corre E, Rondeau E, Benhamou Y, Bachet A, Stépanian A, Veyradier A; Centre de référence des microangiopathies thrombotiques. Rev Med Interne. 2015 Dec 8. pii: S0248-8663(15)01047-4.
La révolution des anticorps monoclonaux dans la prise en charge des microangiopathies thrombotiques [The revolution of monoclonal antibodies in the treatment of thrombotic microangiopathy]. Sauvètre G, Grange S, Froissart A, Veyradier A, Coppo P, Benhamou Y.Rev Med Interne. 2015 May;36(5):328-38.
Purpura thrombotique thrombocytopénique et autres syndromes de microangiopathie thrombotique au cours de l’infection par le virus de l’immunodéficience humaine. Gilardin L, Malak S, Schoindre Y, Galicier L, Veyradier A, Coppo P. Rev Med Interne. 2012 Jan 24. PubMed PMID: 22280852. 
ADAMTS13, la protéase spécifique du clivage du facteur von Willebrand. Veyradier A, Coppo P. Med Sci (Paris). 2011 Dec;27(12):1097-105.
Le syndrome hémolytique et urémique atypique: où en est-on en 2011 ? Chantal Loirat, Fadi Fakhouri, Arnaud Garnier, Frank Bienaimé, Anne-Laure Sellier-Leclerc, Véronique Frémeaux-Bacchi.
Purpura thrombotique thrombocytopénique par déficit héréditaire en ADAMTS13 (syndrome d’Upshaw-Schulman) : actualités et perspectives. Veyradier A, Loirat C, Girma JP, Ribba AS, Wolf M, Coppo P, Meyer D. Hématologie 2005 ; 11 (5) : 321-34
 
ARTICLES EN ANGLAIS
Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French Thrombotic Microangiopathies Reference Centre. Grall M, Azoulay E, Galicier L, Provôt F, Wynckel A, Poullin P, Grange S, Halimi JM, Lautrette A, Delmas Y, Presne C, Hamidou M, Girault S, Pène F, Perez P, Kanouni T, Seguin A, Mousson C, Chauveau D, Ojeda-Uribe M, Barbay V, Veyradier A, Coppo P, Benhamou Y.
Am J Hematol. 2017 Jan 30. doi: 10.1002/ajh.24665.
Understanding therapeutic targets in thrombotic thrombocytopenic purpura. Joly BS, Vanhoorelbeke K, Veyradier A. Intensive Care Med. 2017 Jan 23. doi: 10.1007/s00134-016-4662-3.
Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms. Coppo P; French Reference Center for Thrombotic Microangiopathies. Transfus Apher Sci. 2016 Dec 30. pii: S1473-0502(16)30205-1.
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura. J Thromb Haemost. 2017 Feb;15(2):312-322.
Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura. Le Besnerais M, Favre J, Denis CV, Mulder P, Martinet J, Nicol L, Levesque H, Veyradier A, Kopić A, Motto DG, Coppo P, Richard V, Benhamou Y. J Thromb Haemost. 2016 Oct;14(10):1917-1930.
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Joly BS, Stepanian A, Leblanc T, Hajage D, Chambost H, Harambat J, Fouyssac F, Guigonis V, Leverger G, Ulinski T, Kwon T, Loirat C, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies. Lancet Haematol. 2016 Nov;3(11):e537-e546.
Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome: A case report and literature review. Deville C, Garrouste C, Coppo P, Evrard B, Lautrette A, Heng AE. Medicine (Baltimore). 2016 Sep;95(39):e5007.
Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study. Benhamou Y, Paintaud G, Azoulay E, Poullin P, Galicier L, Desvignes C, Baudel JL, Peltier J, Mira JP, Pène F, Presne C, Saheb S, Deligny C, Rousseau A, Féger F, Veyradier A, Coppo P; French Reference Center for Thrombotic Microangiopathies. Am J Hematol. 2016 Dec;91(12):1246-1251.
[Telemedicine in thrombotic microangiopathies: A way forward in rare diseases requiring emergency care]. Coppo P, Corre E, Rondeau E, Benhamou Y, Bachet A, Stépanian A, Veyradier A; Centre de référence des microangiopathies thrombotiques. Rev Med Interne. 2016 Aug;37(8):514-20.
Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Soucemarianadin M, Benhamou Y, Delmas Y, Pichereau C, Maury E, Pène F, Halimi JM, Presne C, Thouret JM, Veyradier A, Coppo P. Eur J Haematol. 2016 Aug;97(2):183-91.
Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors. Martino S, Jamme M, Deligny C, Busson M, Loiseau P, Azoulay E, Galicier L, Pène F, Provôt F, Dossier A, Saheb S, Veyradier A, Coppo P; French Reference Center for Thrombotic Microangiopathies. PLoS One. 2016 Jul 6;11(7):e0156679.
Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease. London J, Boutboul D, Agbalika F, Coppo P, Veyradier A, Gérard L, Oksenhendler E, Azoulay E, Galicier L. Br J Haematol. 2016 May 25.
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P, Poullin P, de Maistre E, Provôt F, Delmas Y, Perez P, Benhamou Y, Stepanian A, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies. Lancet Haematol. 2016 May;3(5):e237-45.
The European Hematology Association Roadmap for European Hematology Research: a consensus document. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. Haematologica. 2016 Feb;101(2):115-208.
Von Willebrand Factor--A New Target for TTP Treatment? Veyradier A. N Engl J Med. 2016 Feb 11;374(6):583-5.
[Thrombotic thrombocytopenic purpura in a newborn]. hariani I, Jmili-Braham N, Azzebi O, Kortas M, Veyradier A, Bakir L. Arch Pediatr. 2016 Jan;23(1):78-81.
Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange. Coppo P, Froissart A; French Reference Center for Thrombotic Microangiopathies. Hematology Am Soc Hematol Educ Program. 2015 Dec 5;2015(1):637-43.
Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story. Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P; French Reference Center for Thrombotic Microangiopathies. Eur J Intern Med. 2015 Nov;26(9):659-65.
Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura. Roriz M, Landais M, Desprez J, Barbet C, Azoulay E, Galicier L, Wynckel A, Baudel JL, Provôt F, Pène F, Mira JP, Presne C, Poullin P, Delmas Y, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Chauveau D, Veyradier A, Halimi JM, Hamidou M,Coppo P; French Thrombotic Microangiopathies Reference Center. Medicine (Baltimore). 2015 Oct;94(42):e1598.
Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study. Toussaint-Hacquard M, Coppo P, Soudant M, Chevreux L, Mathieu-Nafissi S, Lecompte T, Gross S, Guillemin F, Schneider T. Transfusion. 2015 Oct;55(10):2445-51.
Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC. de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, Bay JO, Neven B, Moussi J, Simon L, Xhaard A, Resche-Riggon M, O'Meara A, Fremeaux-Bacchi V, Veyradier A, Socié G, Coppo P, de Latour RP. Transplantation. 2015 Sep;99(9):1953-9.
Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease. Delmas Y, Helou S, Chabanier P, Ryman A, Pelluard F, Carles D, Boisseau P, Veyradier A, Horovitz J, Coppo P, Combe C. BMC Pregnancy Childbirth. 2015 Jun 17;15:137.
Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center. Benhamou Y, Baudel JL, Wynckel A, Galicier L, Azoulay E, Provôt F, Pène F, Mira JP, Presne C, Poullin P, Halimi JM, Rivière E, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Hamidou M, Chauveau D, Veyradier A, Coppo P. Am J Hematol. 2015 Jun;90(6):E127-9.
Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. Benhamou Y, Boelle PY, Baudin B, Ederhy S, Gras J, Galicier L, Azoulay E, Provôt F, Maury E, Pène F, Mira JP, Wynckel A, Presne C, Poullin P, Halimi JM, Delmas Y, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Hamidou M, Cohen A, Veyradier A, Coppo P; Reference Center for Thrombotic Microangiopathies. J Thromb Haemost. 2015 Feb;13(2):293-302.
Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement. Joly B, Stepanian A, Hajage D, Thouzeau S, Capdenat S, Coppo P, Veyradier A. Thromb Res. 2014 Nov;134(5):1074-80.
Circulating endothelial cells and progenitors as prognostic factors during autoimmune thrombotic thrombocytopenic purpura: results of a prospective multicenter French study. Widemann A, Pasero C, Arnaud L, Poullin P, Loundou AD, Choukroun G, Sanderson F, Lacroix R, Sabatier F, Coppo P, Dignat-George F, Kaplanski G; ENDO-13 study group. J Thromb Haemost. 2014 Oct;12(10):1601-9.
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Hie M, Gay J, Galicier L, Provôt F, Presne C, Poullin P, Bonmarchand G, Wynckel A, Benhamou Y, Vanhille P, Servais A, Bordessoule D, Coindre JP, Hamidou M, Vernant JP, Veyradier A, Coppo P; French Thrombotic Microangiopathies Reference Centre. Blood. 2014 Jul 10;124(2):204-10.
High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center. Morgand M, Buffet M, Busson M, Loiseau P, Malot S, Amokrane K, Fortier C, London J, Bonmarchand G, Wynckel A, Provôt F, Poullin P, Vanhille P, Presne C, Bordessoule D, Girault S, Delmas Y, Hamidou M, Mousson C, Vigneau C, Lautrette A, Pourrat J, Galicier L, Azoulay E, Pène F, Mira JP, Rondeau E, Ojeda-Uribe M, Charron D, Maury E, Guidet B, Veyradier A, Tamouza R, Coppo P; Thrombotic Microangiopathies Reference Center. Transfusion. 2014 Feb;54(2):389-97.
Evaluation of a commercial assay for ADAMTS13 activity measurement. Thouzeau S, Capdenat S, Stépanian A, Coppo P, Veyradier A. Thromb Haemost. 2013 Oct;110(4):852-3.
Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D, Socié G. Br J Haematol. 2013 Apr;161(2):279-80.
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Benhamou Y, Assié C, Boelle PY, Buffet M, Grillberger R, Malot S, Wynckel A, Presne C, Choukroun G, Poullin P, Provôt F, Gruson D, Hamidou M, Bordessoule D, Pourrat J, Mira JP, Le Guern V, Pouteil-Noble C, Daubin C, Vanhille P, Rondeau E, Palcoux JB, Mousson C, Vigneau C, Bonmarchand G, Guidet B, Galicier L, Azoulay E, Rottensteiner H, Veyradier A, Coppo P; Thrombotic Microangiopathies Reference Center. Haematologica. 2012 Aug;97(8):1181-6
Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Moatti-Cohen M, Garrec C, Wolf M, Boisseau P, Galicier L, Azoulay E, Stepanian A, Delmas Y, Rondeau E, Bezieau S, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies. Blood. 2012 Jun 14;119(24):5888-97.
Thrombotic microangiopathies: from empiricism to targeted therapies. Coppo P. Presse Med. 2012 Mar;41(3 Pt 2):e101-4.
Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Coppo P, Veyradier A. Presse Med. 2012 Mar;41(3 Pt 2):e163-76.
Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Beloncle F, Buffet M, Coindre JP, Munoz-Bongrand N, Malot S, Pène F, Mira JP, Galicier L, Guidet B, Baudel JL, Subra JF, Tanguy-Schmidt A, Pourrat J, Azoulay E, Veyradier A, Coppo P. Transfusion. 2012 Mar 8. PubMed PMID: 22404639.
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P. Crit Care Med. 2012 Jan;40(1):104-111.
Atypical hemolytic uremic syndrome. Loirat C, Frémeaux-Bacchi V. Orphanet J Rare Dis. 2011 Sep 8;6:60.
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J, Girault S, Bordessoule D, Saheb S, Ramakers M, Hamidou M, Vernant JP, Guidet B, Wolf M, Veyradier A; French Reference Center for Thrombotic Microangiopathies. PLoS One. 2010 Apr 23;5(4).
HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic  thrombocytopenic purpura in Caucasians. Coppo P, Busson M, Veyradier A, Wynckel A, Poullin P, Azoulay E, Galicier L, Loiseau P; French Reference Centre For Thrombotic Microangiopathies. J Thromb Haemost. 2010 Apr;8(4):856-9.
Cancer awareness in atypical thrombotic microangiopathies. Oberic L, Buffet M, Schwarzinger M, Veyradier A, Clabault K, Malot S, Schleinitz N, Valla D, Galicier L, Bengrine-Lefèvre L, Gorin NC, Coppo P; Reference Center for the Management of Thrombotic Microangiopathies. Oncologist. 2009 Aug;14(8):769-79.
Thrombotic microangiopathies: towards a pathophysiology-based classification. Coppo P, Veyradier A. Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):36-50. Revue.
Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity. Malak S, Wolf M, Millot GA, Mariotte E, Veyradier A, Meynard JL, Korach JM, Malot S, Bussel A, Azoulay E, Boulanger E, Galicier L, Devaux E, Eschwège V, Gallien S, Adrie C, Schlemmer B, Rondeau E, Coppo P; Réseau d’Étude des Microangiopathies Thrombotiques  (TMA-Rare Diseases Reference Center). Scand J Immunol. 2008 Sep;68(3):337-44.
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A; French Clinical and Biological Network on Adult Thrombotic Microangiopathies. Blood. 2007 Apr 1;109(7):2815-22.
Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pène F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Br J Haematol. 2006 Jan;132(1):66-74. Revue.
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Frémeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Medicine (Baltimore). 2004 Jul;83(4):233-44.
Infectious diseases as a trigger in thrombotic microangiopathies in intensive care unit (ICU) patients ? Coppo P, Adrie C, Azoulay E, Leleu G, Oksenhendler E, Galicier L, Le Gall JR, Bussel A, Schlemmer B. Intensive Care Med. 2003 Apr;29(4):564-9.
Mis à jour le 24 Février 2017